CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia.

摘要: Metabolic disturbances are more prevalent in patients with schizophrenia (SCZ) than the general population. The endocannabinoid system plays an important role regulation of dopamine transmission and several metabolic pathways, receptor type 1 gene (CNR1) is considered a candidate for both SCZ disorders. We examined whether genetic variation CNR1 was associated syndrome (MetS) naturalistic cohort 407 SCZ. minor alleles rs6928499, rs1535255, rs2023239 were nominally lower risk MetS [odds ratio (OR), 0.56; 95% confidence interval (CI), 0.37-0.84; P = 0.006; OR, CI, 0.44; 0.27-0.72; 0.001, respectively, adjusted age, sex, duration illness, clozapine or olanzapine treatment). These differences mainly due to high-density lipoprotein cholesterol fasting glucose but not body mass index waist circumference. No significant association other polymorphisms (rs806377, rs1049353, rs6454674, rs806379) found. results provide evidence that prevalence during long-term treatment antipsychotic treatment. Further studies needed uncover exact molecular basis this association, which could novel targets MetS.